IQUIFIB   02644
INSTITUTO DE QUIMICA Y FISICOQUIMICA BIOLOGICAS "PROF. ALEJANDRO C. PALADINI"
Unidad Ejecutora - UE
artículos
Título:
Potentation of omega-3 fatty acid antidepresant like effect.
Autor/es:
CARLOS HORACIO LAINO,; HORACIO FONSECA; STERIN SPEZIALE, NORMA BEATRIZ; NORA SLOBODIANIK ; ANALÍA REINÉS
Revista:
EUROPEAN JOURNAL OF PHARMACOLOGY
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Lugar: Nueva York; Año: 2010 vol. 648 p. 117 - 126
ISSN:
0014-2999
Resumen:
Despite the advances in psychopharmacology, the treatment of depressive disorders is
still not satisfactory. Side effects and resistance to antidepressant drugs are the greatest
complications during treatment. Based on recent evidence, omega-3 fatty acids may
influence vulnerability and outcome in depressive disorders. The aim of this study was
to further characterize the omega-3 antidepressant-like effect in rats in terms of its
behavioral features in the depression model forced swimming test either alone or in
combination with antidepressants fluoxetine or mirtazapine. Ultimately, we prompted to
determine the lowest dose at which omega-3 fatty acids and antidepressant drugs may
still represent a pharmacological advantage when employed in combined treatments.
Chronic diet supplementation with omega-3 fatty acids produced concentrationdependent
antidepressant-like effects in the forced swimming test displaying a
behavioral profile similar to fluoxetine but different from mirtazapine. Fluoxetine or
mirtazapine at antidepressant doses (10 and 20 mg/kg/day, respectively) rendered
additive effects in combination with omega-3 fatty acid supplementation (720
mg/kg/day). Beneficial effects of combined treatment were also observed at subeffective
doses (1 mg/kg/day) of fluoxetine or mirtazapine, since in combination with
omega-3 fatty acids (720 mg/kg/day), antidepressants potentiated omega-3
antidepressant-like effects. The antidepressant-like effects occurred in the absence of
changes in brain phospholipid classes. The therapeutic approach of combining omega-3
fatty acids with low ineffective doses of antidepressants might represent benefits in the
treatment of depression, especially in patients with depression resistant to conventional
treatments and even may contribute to patient compliance by decreasing the magnitude
of some antidepressant dose-dependent side effects.